Healthcare planning software developer Hospital IQ secured $25m in a Baxter-led round while augmented reality platform developer Ubiquity6 and infant product retailer Mumzworld have been acquired.

The surgical technology developer was valued at $3bn in a series C round backed by returning investor Cambridge Innovation Capital.

The Stanford spinout has gone public following a $238m IPO, after revealing that the university was also among the series B investors.

Karolinska Development-backed Biosergen has begun trading on the Nasdaq First Growth Market, having already undertaken a $5.9m offering earlier this month.

Partly based on research at University of Washington, KenSci has agreed to an acquisition by Tegria for an undisclosed sum.

The Asahi Kasei and Shenzhen Hepalink-backed microbial detection system provider has amassed over $340m of funding before filing for an initial public offering.

The cancer drug developer is set to float on the Nasdaq Global Select Market, presenting an opportunity for strategic investors Pharmaron, Celgene, Amgen and Merck & Co to exit.

Taikang Insurance Group’s asset management arm has co-led the second tranche of an $83m round for the autism and speech therapy provider.

University of Oxford and OSI are set to exit the medical diagnostics software provider in a flotation with a $75m placeholder target.

The surgical technology developer was valued at $3bn in a series C round co-led by SoftBank Vision Fund 2 and backed by Tencent and GE Healthcare.